FDA Pre-Approval Inspection (PAI): 10-Step Preparation Guide and Checklist

An FDA Pre-Approval Inspection can materially affect whether a manufacturing facility is considered acceptable to support approval of a drug application. The inspection connects three things that are often managed separately: the commitments made in the application, the operations occurring at the site and the original data supporting the product's quality.

That is why PAI preparation cannot be reduced to cleaning the facility, organizing a document room or coaching employees a few weeks before FDA arrives. A site must be able to demonstrate commercial manufacturing readiness, conformance to the filed Chemistry, Manufacturing and Controls information, reliable data and an effective pharmaceutical quality system. Any gap between the submission and shop-floor reality can become an approval risk.

This guide explains how to prepare for an FDA Pre-Approval Inspection under FDA's current 2026 framework. If your facility, sponsor or contract manufacturer is approaching an application milestone, BioBoston Consulting provides FDA PAI readiness and mock inspection support, including independent assessments led by former FDA investigators and senior quality professionals. You can also contact BioBoston to discuss your sites, application and target timeline.

Regulatory update: FDA issued a revised Compliance Program 7346.832 on June 29, 2026, with an implementation date of August 10, 2026. The revised program strengthens FDA's risk-based approach and identifies four PAI objectives. This article reflects that current framework.

What is an FDA Pre-Approval Inspection?

A Pre-Approval Inspection, commonly called a PAI, is an FDA inspection used to support the assessment of a pending marketing application. For human drug manufacturing facilities named in an NDA or ANDA, FDA evaluates whether the establishment can perform the proposed operations in accordance with current good manufacturing practice, whether site operations conform to the application and whether the data submitted to FDA are complete, accurate and reliable.

A PAI is product- and application-connected. It is different from a routine surveillance inspection, although FDA may expand or combine coverage when circumstances warrant. A surveillance inspection generally evaluates ongoing CGMP compliance across marketed operations. A PAI focuses on whether the facility and evidence support the pending application. Significant systemic issues discovered during a PAI may lead FDA to broaden its review.

FDA's current Compliance Program 7346.832 for Preapproval Inspections applies to manufacturing facilities supporting pending NDAs and ANDAs. FDA uses the inspection results together with the application assessment and other facility information when deciding whether the facility is acceptable from a quality perspective.

PAI versus PLI for biological products

Terminology matters for biologics. FDA's April 2026 Compliance Program 7346.832M governs prelicense and preapproval inspections of CDER-regulated biological product manufacturers. Under that program, a Prelicense Inspection, or PLI, generally supports an original BLA, while a PAI can support a supplement involving a significant manufacturing change to a licensed product.

The readiness principles overlap, but the governing program and product-specific expectations differ. Sponsors should confirm which FDA center, application type, facility operations and compliance program apply. This guide focuses primarily on drug PAIs under Program 7346.832 while highlighting biologics distinctions where relevant.

When may FDA conduct a Pre-Approval Inspection?

Not every facility named in every application automatically receives an on-site PAI. FDA conducts a preapproval facility evaluation and uses a holistic, risk-based assessment to decide whether an inspection is needed and what its scope should cover.

FDA may consider factors such as:

• The facility's compliance status and inspection history
• Whether previously inspected operations are relevant to the proposed product
• The novelty or complexity of the drug and manufacturing process
• The site's experience with the proposed dosage form, technology or scale
• Changes to the facility, equipment, process, quality system, management or corporate structure
• Recalls, complaints, Field Alert Reports, MedWatch reports or other hazard signals
• The reliability and accuracy of information supporting the application
• Whether proposed operations match the descriptions and commitments in the application
• Information obtained through records requests, remote evaluations or trusted regulatory partners

A low likelihood of an on-site inspection is not a reason to postpone readiness. FDA's September 2025 guidance on alternative tools for assessing facilities in pending applications states that manufacturing, packaging and control sites should be ready for inspection when the application is submitted. FDA may use records requests, remote regulatory assessments, information from trusted foreign regulators or remote subject-matter experts in advance of, in support of or, in appropriate circumstances, instead of an on-site PAI.

What are FDA's four PAI objectives?

The revised 2026 compliance program identifies four inspection objectives. Understanding these objectives gives teams a more accurate basis for a readiness assessment and mock PAI than a generic CGMP checklist.

Objective 1: Readiness for commercial manufacturing

FDA evaluates whether the establishment's quality system provides sufficient control over the facility and proposed commercial operations. The program breaks this objective into five areas:

• Manufacturing and laboratory capabilities, changes, deviations and development trends have been adequately evaluated.
• Sampling, testing, release and supplier-qualification programs are sound and appropriate.
• Facility and equipment controls are sufficient to prevent contamination of or by the application product.
• Procedures for batch release, change management, investigations, complaints, adverse events and FDA reporting are adequate.
• The proposed commercial process and manufacturing batch record are feasible, scientifically justified and connected to lifecycle process validation.

The 2026 program directs FDA to cover manufacturing and laboratory capability and the feasibility of the proposed commercial process on every PAI. The depth of other readiness areas is risk-based. A site should therefore understand both the baseline coverage and the factors that could expand FDA's scope.

Objective 2: Conformance to application

FDA verifies that the formulation, manufacturing or processing methods, analytical methods and batch records at the site are consistent with the CMC information in the application. This can include exhibit batches, biobatches, pivotal clinical batches and the proposed commercial-scale process.

This objective is covered on every PAI. Readiness requires a controlled reconciliation between the current application, amendments, master records, methods, specifications, equipment, sites and actual operating practices. A team that treats the CMC submission as a regulatory document owned only by Regulatory Affairs can miss differences that are obvious on the manufacturing floor or in the laboratory.

Objective 3: Data integrity audit

FDA audits raw data associated with the product to confirm that information submitted in the CMC section is relevant, accurate, complete and reliable. Investigators may trace a reported result back through electronic and hardcopy records, including chromatograms, spectrograms, analyst notebooks, audit trails, calculations, worksheets, batch records and stability data.

Data integrity coverage is part of every PAI. A site must be able to retrieve original records, explain the complete data lifecycle and account for invalidated, repeated, deleted, aborted or excluded data. BioBoston's data integrity and software implementation support can help teams assess both procedural controls and the practical behavior of regulated systems.

Objective 4: Commitment to quality in pharmaceutical development

The 2026 program adds an explicit objective focused on how the pharmaceutical development program is supported, defined, managed and continually assessed, including how development knowledge supports improvement of the pharmaceutical quality system.

FDA directs coverage of this objective during the initial PAI, periodically during later PAIs based on risk and when major changes have occurred in the quality system, management team or corporate structure. This makes development governance, knowledge transfer, change management and management oversight visible parts of readiness rather than background activities.

What does FDA review during a PAI?

The exact scope depends on the product, process, facility, application-assessment questions and site history. Common areas include:

Application commitments and manufacturing records

• Current CMC sections, amendments, deficiency responses and commitments
• Master production and control records
• Executed records for exhibit, biobatch, pivotal clinical, validation and commercial batches
• Formulation, scale, yields, hold times, reprocessing and rework
• Equipment, facilities, utilities and manufacturing locations
• Technology-transfer packages and comparability assessments

Process understanding and validation

• Development studies and identification of critical quality attributes
• Critical material attributes, process parameters and sources of variability
• Scale-up rationale and commercial-process feasibility
• Stage 1 process design evidence and Stage 2 process performance qualification status
• Continued process verification strategy
• Qualification of facilities, utilities and equipment

FDA's Process Validation: General Principles and Practices describes process validation as a lifecycle activity. BioBoston provides qualification and validation support for facilities, equipment, utilities, processes and documentation.

Laboratory controls, methods and stability

• Analytical method validation, verification and transfer
• Specifications, sampling plans, calculations and release testing
• Out-of-specification and out-of-trend investigations
• Stability protocols, storage conditions, pulls, testing and reported results
• Reference standards, reagents, instruments, calibration and maintenance
• Computerized systems, audit trails, access controls and backup practices

Quality systems and management oversight

• Quality-unit authority and independence
• Deviations, investigations, CAPA and effectiveness checks
• Change control and evaluation of application-reporting impact
• Complaint handling and Field Alert Reporting
• Supplier qualification, material controls and contractor oversight
• Training, personnel qualification and management review
• Data governance, document control and record retention

The applicable CGMP requirements include 21 CFR Part 210 and 21 CFR Part 211, along with other product- and operation-specific requirements.

How to prepare for an FDA PAI in 10 steps

1. Establish cross-functional PAI governance

Appoint one readiness leader with authority to coordinate the applicant, manufacturing site, Quality, Regulatory Affairs, CMC, Manufacturing, Engineering, Validation, QC, IT, Supply Chain and contract partners. Define a steering team, workstream owners, subject-matter experts, alternates and executive decision makers.

Document how issues will be escalated and how changes to the application or site will be assessed. This prevents a common failure pattern: each function believes another team owns the gap until the inspection date is close. The applicant remains responsible for coordinating the application story even when important operations are performed by a CDMO, contract laboratory, API supplier or packaging site.

2. Build a product- and facility-specific risk map

Start with the questions FDA is likely to ask about this product at this facility, not with a generic audit template. Review the current application, facility responsibilities, product and process complexity, inspection history, previous observations, recalls, complaints, Field Alert Reports, recent changes and unresolved quality signals.

Map each risk to the relevant 2026 PAI objective, evidence, owner and remediation deadline. Distinguish between issues that could affect application approval, issues that indicate systemic CGMP risk and improvements that are valuable but not on the critical path. BioBoston's gap assessment and remediation services can provide an independent, risk-prioritized view.

3. Reconcile the application with actual site operations

Create an application-to-floor traceability matrix. For each important CMC commitment, identify the source section, current approved or pending text, site record, process owner and verification status. Cover the product formula, manufacturing steps, equipment, scale, sites, process parameters, in-process controls, analytical methods, specifications, container-closure system, storage conditions and stability commitments.

Investigate every difference. Some differences may require a documentation correction, change control, scientific justification, comparability assessment or application amendment. Do not rely on informal explanations during the inspection. The site, applicant and submission must present one controlled version of the truth. BioBoston's regulatory CMC support can help connect submission commitments with manufacturing and quality evidence.

4. Demonstrate commercial manufacturing readiness

Confirm that the proposed process is feasible at commercial scale and that the site can execute it consistently. Review development knowledge, scale-up, technology transfer, facility and equipment capability, utilities, material flows, contamination controls, staffing, maintenance, calibration and supply availability.

Process-validation status should be transparent and scientifically defensible. FDA's current compliance program states that an approval-withhold recommendation should not be made solely because full commercial-scale process validation is incomplete at the time of the PAI. That does not excuse failed PPQ work, an uncontrolled process or insufficient development evidence. Before product distribution, the manufacturer must have a high degree of assurance that the process consistently produces acceptable quality.

5. Challenge laboratory and stability readiness

Review each application-relevant analytical method from source data through the reported result. Confirm method validation or verification status, method transfer, system suitability, sample preparation, calculations, specifications, reference standards, instrument qualification and analyst training.

Trace stability results from the application to raw records and examine the complete study history. Investigate missed pulls, atypical trends, invalidated runs, changed methods, storage excursions and discrepancies between summary tables and original data. Ensure that laboratory investigations reach a scientifically supported root cause or a defensible conclusion when no root cause can be confirmed.

6. Perform a focused data-integrity assessment

Data integrity is not only an IT exercise. Examine how people create, review, change, invalidate, transfer, retain and report data across paper and electronic workflows. Test whether user access is appropriate, audit trails are reviewed, metadata are retained, clocks are synchronized, backups are recoverable and original records can be reconstructed.

Use data tracing to compare selected application values with their complete source context. Look for unofficial worksheets, shared credentials, disabled audit trails, uncontrolled exports, unexplained reintegration, repeated testing, deleted sequences, missing notebooks, abandoned records and incomplete review. FDA's Data Integrity and Compliance With Drug CGMP guidance provides questions and answers on the agency's expectations.

7. Strengthen investigations, CAPA and change control

PAI readiness depends on how the site responds when something goes wrong. Review development and commercial-scale deviations, atypical events, OOS results, maintenance failures, environmental excursions, complaints and prior audit findings. Investigations should define the problem, assess product and patient impact, establish an evidence-based scope, identify root cause when possible and address systemic risk.

Check that CAPAs are specific, resourced, completed on realistic timelines and tested for effectiveness. Review whether changes were evaluated for their impact on validation, comparability, stability, regulatory commitments and application reporting. A large number of administratively closed records is not persuasive if repeat events show that underlying causes remain.

8. Verify supplier and contract-site control

Map every facility and third party that manufactures, tests, packages, labels, stores or supplies a critical component. Confirm that quality agreements match actual responsibilities and application disclosures. Review qualification, audit status, performance monitoring, change notification, deviations, data access and escalation mechanisms.

The applicant and inspected site should be able to explain how external data and operations are controlled. Ensure records can be retrieved promptly across time zones and organizational boundaries. BioBoston can support internal and supplier audits as well as multi-site readiness and remediation.

9. Conduct an independent mock PAI and verify remediation

A useful mock PAI follows the likely FDA objectives and application-specific risks. It should include a facility walkthrough, live document requests, interviews, batch and laboratory data tracing, application-conformance checks and pressure testing of the inspection-management process.

Use an independent lead who can challenge assumptions and observe what internal teams have normalized. The output should classify findings by potential regulatory and approval impact, identify supporting evidence, assign owners and set practical deadlines. A second verification step should confirm that critical corrections were implemented and effective. A report without remediation ownership creates awareness, not readiness.

10. Prepare people, logistics and the response process

Train employees on their actual roles. Subject-matter experts should answer the question asked, distinguish facts from assumptions, explain records in context and know when to seek clarification. They should not guess, over-explain, argue or offer commitments without authorization. Practice with realistic interviews and follow-up questions.

Establish the inspection room, back room, escorts, note takers, document reviewers, request log, copying and redaction rules, communication channels and daily debrief process. Test document retrieval under time pressure. Prepare equivalent workflows for a section 704(a)(4) records request or remote interactive evaluation, including secure file transfer, video capability, screen sharing and rapid technical support.

Finally, identify the team that will assess any observations, coordinate immediate containment and draft a response. Readiness continues through the final facility recommendation; it does not end at the closing meeting.

FDA PAI preparation checklist

Use this checklist as a high-level readiness screen. It should be tailored to the application, product, sites, manufacturing technology and FDA program.

Governance and scope

• A PAI leader, steering team, workstream owners and executive decision makers are assigned.
• Each FDA-listed facility and its application responsibilities have been confirmed.
• Current inspection history, commitments, open observations and quality signals have been assessed.
• Risks are mapped to FDA's current PAI objectives, evidence and remediation owners.
• Critical issues have escalation routes and decision deadlines.

Application conformance

• The current CMC application, amendments and responses are available to responsible site SMEs.
• An application-to-floor traceability matrix has been completed.
• Formula, process, scale, equipment, sites, methods, specifications and storage conditions have been reconciled.
• Differences are resolved through controlled changes, scientific justification or regulatory action.
• Commitments made in deficiency responses or meetings have been implemented or are tracked.

Manufacturing and validation

• The commercial process is feasible and supported by development and scale-up evidence.
• Master records are complete, approved and consistent with the application.
• Facilities, utilities and equipment are qualified for proposed operations.
• Process-validation strategy and current PPQ status are scientifically defensible.
• Critical parameters, material attributes, hold times, yields and controls are supported.
• Contamination and cross-contamination risks are adequately controlled.

Laboratory, stability and data integrity

• Methods are appropriately validated, verified or transferred.
• Application values can be traced to complete raw data.
• OOS, OOT, invalidated, repeated and aborted tests are scientifically investigated.
• Stability protocols, pulls, conditions, results and trends reconcile with the application.
• Audit trails, access controls, metadata, backup and record-retention controls are effective.
• Paper and electronic records are attributable, legible, contemporaneous, original and accurate.

Pharmaceutical quality system

• The quality unit has clear authority and adequate resources.
• Deviations and investigations address root cause, scope and product impact.
• CAPAs are implemented, evidence-based and checked for effectiveness.
• Change controls evaluate validation, stability and regulatory-reporting impact.
• Complaints, Field Alert Reports and adverse quality signals are handled appropriately.
• Supplier and contractor qualification is current and risk-based.
• Management review identifies trends, repeat issues and resource needs.

People and inspection operations

• SMEs, alternates, escorts, scribes and document-room personnel are identified.
• Role-based interview training and realistic practice have been completed.
• Front-room, back-room and remote-assessment workflows have been tested.
• Document requests can be logged, reviewed, approved and fulfilled promptly.
• A daily debrief and issue-escalation process is defined.
• A post-inspection and Form FDA 483 response team is ready.

How early should PAI preparation begin?

There is no universal timetable. A mature site producing a familiar dosage form may require a different plan from a new facility, first commercial product, complex biologic or process still undergoing scale-up. Build the schedule from the application filing date, FDA action timeline, remaining validation work and the time needed to implement and verify remediation.

Nine to twelve months before the expected inspection window

• Establish governance and complete the initial product-specific gap assessment.
• Reconcile the application, technology-transfer package and proposed commercial process.
• Identify major facility, validation, laboratory, data-integrity and supplier risks.
• Start remediation that requires capital, system changes, new studies or substantial training.

Approximately six months before

• Review progress against critical risks and application commitments.
• Conduct focused audits of laboratories, electronic systems, validation and contract partners.
• Complete or advance major CAPAs and collect implementation evidence.
• Begin document-index and inspection-management design.

Approximately 60 to 90 days before

• Conduct an independent mock PAI using realistic document and data requests.
• Prioritize findings based on approval, product-quality and CGMP risk.
• Train SMEs and test front-room and back-room workflows.
• Verify that application-conformance and data-trace exercises can be completed consistently.

Final 30 days

• Verify closure or controlled status of critical mock-inspection findings.
• Refresh training, contact lists, SME schedules and escalation paths.
• Run final document-retrieval, facility-tour and technology checks.
• Confirm that new changes, deviations and data since the mock PAI have been assessed.

These timeframes are planning ranges, not FDA requirements. If the organization has less time, focus first on risks that could affect application conformance, data reliability, manufacturing control or patient and product safety. Avoid superficial document polishing that leaves underlying systems unchanged.

What should a company expect during the PAI?

Opening meeting and scope confirmation

FDA personnel generally introduce the inspection, present appropriate credentials and notices, explain the purpose and request an overview of the facility and proposed operations. The company should confirm the inspection contacts, communication process, working space, operating schedule and document-request method without trying to limit FDA's lawful scope.

Facility walkthrough

The walkthrough allows investigators to compare the facility and operations with the application and records. Employees should follow normal procedures. Staged behavior, unusual cleaning or unexplained operational changes can create more questions than they prevent. Escorts should document requests and observations without obstructing the inspection.

Document review and data tracing

Investigators may move from an application value or batch result to the complete supporting record, then follow related deviations, change controls, audit trails, equipment logs, analyst activity or material history. The response team should provide accurate, reviewed records promptly and track exactly what was supplied.

SME interviews

FDA may interview personnel who perform, review or approve work. Effective SMEs explain what they personally know, use records when needed and acknowledge when another person is the correct expert. Consistent answers come from consistent systems and training, not memorized scripts.

Daily discussions and closing meeting

Daily debriefs help the company understand emerging concerns, correct factual misunderstandings and plan evidence-based follow-up. At the closing meeting, FDA discusses inspectional observations and may issue Form FDA 483. The company should seek clarification where needed, avoid unsupported promises and begin a risk-based response process immediately.

What are the possible PAI outcomes?

Under the current program, FDA ultimately records an approve or withhold recommendation for the facility in relation to the application. An approve recommendation means FDA did not identify significant issues that would adversely affect the establishment's ability to perform its designated functions in the application. It does not by itself approve the marketing application.

A withhold recommendation may result when significant deficiencies affect the site's designated functions. FDA's 2026 program gives examples that include:

• Significant data-integrity problems or misrepresented submission data
• Serious CGMP concerns affecting pivotal, exhibit, biobatch or validation batches
• Significant differences between pivotal or biobatch processes and proposed commercial operations
• Incomplete manufacturing instructions or insufficient supporting data
• Lack of capacity or readiness to manufacture the proposed product
• Failure to meet application commitments
• Failed full-scale PPQ work showing that the process is not controlled
• Incomplete or unsuccessful analytical method validation or verification
• Significant stability failures or failure to report adverse quality findings
• Delaying, denying, limiting or refusing an inspection

What happens if FDA issues Form FDA 483?

Form FDA 483 lists conditions or practices that investigators observed and consider potentially objectionable. It is not FDA's final compliance determination. A prompt, credible response can still be important to the agency's evaluation of the facility and application.

FDA's March 2026 draft guidance on responding to Form FDA 483 observations after a drug CGMP inspection recommends that firms choosing to respond do so within 15 business days. Because this document is draft guidance, teams should follow the instructions provided by FDA for the specific inspection and confirm current requirements.

A strong response should address the observation and its underlying system, explain immediate containment, assess product and patient risk, define the investigation and root cause, present completed and planned CAPAs, establish realistic dates and describe effectiveness checks. Where work cannot be completed within the initial response period, include interim controls, accountable owners, milestones and a follow-up reporting plan. BioBoston provides CAPA and remediation execution support, not only response drafting.

Common PAI preparation mistakes that create avoidable risk

Starting only after FDA announces the inspection

Facility, process, laboratory and data-integrity gaps may require months to correct and verify. Readiness should be integrated into application and commercial-launch planning.

Using a generic inspection checklist

A broad CGMP review can miss the defining PAI question: whether this site's operations and data support this application. Build the assessment around the product, facility, submission and FDA's current objectives.

Failing to reconcile the CMC submission with the shop floor

Regulatory Affairs may know what was filed while Operations knows what is performed. Unless those views are formally reconciled, differences in process, equipment, methods, sites or scale may remain hidden until FDA asks.

Reviewing summary reports without tracing raw data

A clean report does not prove that the source records are complete. Mock PAI work should follow selected results through raw data, metadata, audit trails, calculations, invalidated testing and review history.

Closing CAPAs administratively without verifying effectiveness

Repeat deviations, recurring OOS patterns and long-open investigations may show that actions did not correct the system. FDA evaluates what the quality system achieves, not only whether forms are marked complete.

Training SMEs to memorize answers

Scripts can break down under follow-up questions and reduce credibility. Train SMEs to understand their processes, use evidence, answer precisely and escalate appropriately.

Ignoring remote and records-based readiness

FDA may use a records request or remote regulatory assessment during the application evaluation. Slow retrieval, disorganized files or weak remote technology can affect the review even without an on-site visit.

Treating the mock PAI report as the finish line

A mock inspection creates value only when critical findings are remediated, evidence is controlled and effectiveness is verified before FDA evaluates the site.

How BioBoston Consulting supports FDA PAI readiness

PAI preparation can strain a team already managing validation, submission questions, commercial launch and daily operations. BioBoston Consulting can provide a focused independent assessment or an integrated readiness team that works alongside the applicant, manufacturing site and contract partners.

BioBoston has a network of more than 650 senior life sciences experts across quality, regulatory affairs, CMC, manufacturing, validation, laboratories and data integrity. The network includes former FDA investigators and professionals with decades of hands-on experience. Engagements can be scoped for one workstream, one site or a multi-site program and can expand into remediation when the assessment identifies urgent gaps.

PAI readiness support can include:

• PAI strategy, governance and risk-based readiness planning
• Independent mock PAI led by a former FDA investigator or senior quality expert
• Application-to-floor CMC conformance assessment
• Commercial manufacturing and process-validation readiness
• Laboratory, stability and analytical-method assessment
• Data-integrity and computerized-system review
• Quality-system, investigation, CAPA and change-control remediation
• Supplier, CDMO and contract-laboratory oversight
• SME interview preparation and role-based GxP training
• Front-room, back-room, remote-assessment and document-control preparation
• Inspection support, daily debriefs and Form FDA 483 response planning
• Post-inspection remediation, effectiveness checks and sustained inspection readiness

BioBoston can also connect the inspection project with quality management system improvement, validation, regulatory CMC support, data integrity and supplier oversight. This reduces the risk that each workstream fixes its own documents while systemic gaps remain between teams.

Frequently asked questions about FDA Pre-Approval Inspections

What is the main purpose of an FDA Pre-Approval Inspection?

A PAI helps FDA determine whether a manufacturing facility named in a pending drug application can perform the proposed operations in accordance with CGMP, whether site practices conform to the application and whether the data supporting the application are complete, accurate and reliable.

Does every NDA or ANDA trigger an on-site PAI?

No. FDA uses a risk-based facility evaluation to decide whether an on-site PAI is needed and what its scope should cover. The decision can consider the product, process, facility, inspection history, compliance status, data reliability and other information. Sites should nevertheless be ready when the application is submitted.

What are the four FDA PAI objectives in the 2026 compliance program?

The four objectives are readiness for commercial manufacturing, conformance to application, data integrity audit and commitment to quality in pharmaceutical development. The last objective is explicit in FDA's revised June 2026 Program 7346.832.

What is the difference between a PAI and a routine FDA inspection?

A PAI is connected to a pending marketing application and evaluates application-specific manufacturing readiness, conformance and data. A surveillance inspection evaluates ongoing CGMP compliance for marketed operations. FDA may combine or expand inspection coverage when appropriate.

What is the difference between a PAI and a PLI?

For CDER-regulated biological products under Program 7346.832M, a PLI generally supports an original BLA, while a PAI can support a supplement involving a significant manufacturing change to an already licensed product. Application type, product and responsible FDA center determine the applicable program.

How long does a Pre-Approval Inspection take?

FDA does not establish one duration for every PAI. The length depends on the assignment, facility, product and process complexity, number of objectives, application questions, records, inspection findings and whether other inspection programs are included. Companies should plan operational coverage based on the announced schedule while remaining prepared for changes in scope.

What should a mock PAI include?

A strong mock PAI should test the current FDA objectives and the application's specific risks. It should include application-to-floor reconciliation, facility walkthroughs, live document requests, batch and laboratory data tracing, SME interviews, inspection logistics and a prioritized remediation plan with verification of critical corrections.

Can FDA use a remote assessment instead of visiting the facility?

In appropriate circumstances, FDA may use alternative tools such as a section 704(a)(4) records request, remote interactive evaluation or information from trusted regulatory partners in advance of, in support of or instead of an on-site PAI. FDA makes that decision case by case; applicants and facilities cannot require the agency to use an alternative tool.

Must commercial-scale process validation be complete before the PAI?

FDA's 2026 drug PAI program states that a withhold recommendation should not be made solely because complete commercial-scale process validation is lacking at the time of the PAI. However, the process must be scientifically supported, failed PPQ work or lack of control can create significant risk, and the firm must establish a high degree of assurance in consistent performance before distribution.

Does receiving Form FDA 483 automatically mean the application will not be approved?

No. Form FDA 483 contains inspectional observations and is not FDA's final compliance or application decision. The nature and significance of the findings, the facility's response, remediation evidence and the complete application assessment can influence FDA's facility recommendation and next actions.

Can BioBoston support only the mock PAI or stay for remediation?

Both options are available. BioBoston can conduct an independent mock PAI and deliver a prioritized report, or continue with CMC reconciliation, validation, data integrity, CAPA, quality-system remediation, training, inspection support and Form FDA 483 response activities. The engagement can be scaled to the facility's risk, timing and internal capacity.

This article is for general educational purposes and does not replace product-specific regulatory, quality, scientific or legal advice. FDA regulations, guidance and compliance programs can change. Confirm the current requirements and inspection instructions applicable to your product, application and facilities.